SEC Filing Summary: PerkinElmer, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for PerkinElmer, Inc. for the period ended October 2, 2005. The company operates in two primary reporting segments: Life and Analytical Sciences and Optoelectronics. During the quarter, the company classified its Fluid Sciences segment and Fiber Optics Test Equipment business as discontinued operations pending divestiture or shutdown.
Key Financial Metrics
| Metric | Three Months Ended Oct 2, 2005 | Nine Months Ended Oct 2, 2005 |
|---|---|---|
| Sales (Continuing Ops) | $361.9 million | $1,092.3 million |
| Operating Income (Continuing Ops) | $40.7 million | $90.2 million |
| Net Income | $31.8 million | $80.6 million |
| Diluted EPS | $0.24 | $0.62 |
| Gross Margin | 43.5% | 43.1% |
| Cash and Equivalents | $166.1 million (Oct 2, 2005) | N/A |
| Long-Term Debt | $268.4 million | N/A |
| Operating Cash Flow (Continuing) | N/A | $107.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 6% year-over-year for both the quarter and the nine-month period. Growth was driven by the Life and Analytical Sciences segment (+6%) and the Optoelectronics segment (+5% to +7%), aided by the acquisition of Elcos AG.
- Margin Expansion: Gross margin improved by 160 basis points for the quarter and 120 basis points for the nine-month period, reaching 43.5% and 43.1% respectively, due to volume increases and productivity improvements.
- Restructuring: The company recorded a pre-tax restructuring charge of $6.0 million for the nine months ended October 2, 2005, primarily related to facility closures in Europe. A separate $8.2 million charge was recorded in Q2 2005 for workforce reductions.
- Discontinued Operations: The company reported income from discontinued operations of $5.5 million for the quarter and $13.3 million for the nine months, offset by a net loss on dispositions of $4.5 million for the nine months (primarily due to the shutdown of the Fiber Optics Test Equipment business).
- Tax Benefit: The nine-month period included a tax benefit of $3.2 million, largely due to a $26.5 million release of reserves from settled tax audits.
Outlook, Risks, and Unusual Items
- Divestitures: The company signed definitive agreements to sell its Aerospace business (to Eaton Corp. for ~$333 million) and Fluid Testing business (to Caleb Brett USA Inc. for ~$34.5 million). Discussions are ongoing for the Semiconductor business.
- Debt Refinancing: In October 2005, the company entered a new $350 million unsecured revolving credit facility. It also completed a tender offer to repurchase approximately $270 million of its 8 7/8% senior subordinated notes.
- Acquisition: The company acquired Elcos AG in February 2005 for approximately $15.4 million in cash plus earn-outs, contributing to Optoelectronics sales.
- Legal Contingencies: Significant patent litigation is ongoing with Enzo Biochem and Amersham Biosciences regarding high-throughput screening technologies. The company believes it has meritorious defenses but cannot estimate potential losses.
- Market Risks: The company faces risks related to foreign currency fluctuations (over 50% of sales are international), cyclical downturns in pharmaceutical and semiconductor markets, and the need for timely new product introductions.
Investor Verification Checklist
- Verify the closing status and regulatory approval of the Aerospace and Fluid Testing divestitures.
- Monitor the impact of the $270 million debt repurchase on future interest expense and liquidity.
- Track the progress of patent litigation with Enzo and Amersham, as outcomes could materially affect operations.
- Assess the integration performance of the Elcos AG acquisition within the Optoelectronics segment.
- Review the remaining restructuring liabilities, particularly lease commitments extending to 2014 under the Q4 2002 plan.